Balyasny Asset Management
ARGS

Balyasny Asset Management’s Argos Therapeutics, Inc. ARGS Stock Holding History

Balyasny Asset Management’s Portfolio ARGS Stock Details ARGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-15,350
Closed -$14K – 2407
2018
Q1 		$14K Buy
+15,350
New +$28.7K ﹤0.01% 1881

Other funds holding ARGS

PI
Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.75B AUM 34.85% 1-Year Est. Return

Balyasny Asset Management's ARGS Position: Q2 2018 in Review

Balyasny Asset Management sold out of Argos Therapeutics, Inc. (ARGS) in Q2 2018, closing a stake of 15,350 shares — an estimated $14K sold.

Balyasny Asset Management first reported a position in ARGS in Q1 2018 and held it in 1 quarter. The position peaked at $14K in Q1 2018. 4 funds tracked by Wall St. Rank hold ARGS as of Q2 2018.

  • Balyasny Asset Management reported no remaining Argos Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
  • Balyasny Asset Management sold 15,350 Argos Therapeutics, Inc. shares in Q2 2018, an estimated $14K.
  • Balyasny Asset Management first reported a position in Argos Therapeutics, Inc. in Q1 2018 and held it in 1 quarter.
  • Balyasny Asset Management's Argos Therapeutics, Inc. position peaked at $14K in Q1 2018.
  • 4 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q2 2018.

Based on Balyasny Asset Management's 13F filing for Q2 2018, filed 14 Aug 2018.